SCHEMBL6037022

SCHEMBL6037022

NNC(=O)CCc1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
CYP3A4 P08684 3/20 0.53
CYP2C19 P33261 3/20 0.53
HIF1A Q16665 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
GAA P10253 3/20 0.51
ESR1 P03372 2/20 0.50
PMP22 Q01453 2/20 0.50
GFER P55789 2/20 0.50
BLM P54132 2/20 0.50
ESR2 Q92731 1/20 0.50
MPO P05164 1/20 0.50
KDM5A P29375 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HCAR2 Q8TDS4 3/20 0.49
KDM4E B2RXH2 4/20 0.49
POLB P06746 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112338 0.89 TRPV1 (0.59) HDAC2HDAC8CYP3A4HIF1AESR1
SCHEMBL8627426 0.87 TRPV1 (0.54) HDAC2HDAC8HDAC1
SCHEMBL17967143 0.82 HDAC1 (0.57) HDAC2HDAC8CYP3A4CYP2C19HIF1A
SCHEMBL2836138 0.82 CYP3A4 (0.53) CYP3A4CYP2C19HIF1ACYP1A2CYP2D6
SCHEMBL8532525 0.82 CYP1A2 (0.51) HDAC2HDAC8CYP3A4CYP2C19HIF1A
SCHEMBL27606163 0.82 LMNA (0.53) CYP3A4CYP2C19HIF1ACYP1A2CYP2D6
SCHEMBL967387 0.82 HDAC2 (0.68) HDAC2HDAC8CYP3A4CYP2C19HIF1A
SCHEMBL8238392 0.82 HDAC8 (0.89) HDAC2HDAC8ESR1ESR2HDAC1
SCHEMBL15092830 0.81 HDAC2 (0.50) HDAC2HDAC8CYP3A4CYP2C19HIF1A
SCHEMBL4409663 0.81 FFAR1 (0.56) HDAC2HDAC8CYP3A4CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121698775-A 1- {2- [3- (4-Hydroxyphenyl) propionyl ] diazinon } behene-1-one, application and preparation method 湖南鼎一致远科技发展股份有限公司 2026-03-20 CN disclosed
CN-118541011-A Polymer material for piezoelectric device 株式会社大阪曹达 2024-08-23 CN disclosed
EP-3762441-A1 POLYURETHANE FOAMS BASED ON POLYETHERCARBONATE POLYOLS Covestro Intellectual Property GmbH & Co. KG (DE) 2021-01-13 EP disclosed
US-20200399466-A1 POLYURETHANE FOAMS BASED ON POLYETHERCARBONATE POLYOLS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2020-12-24 US disclosed
CN-111936542-A Polyurethane foams based on polyether carbonate polyols 科思创知识产权两合公司 2020-11-13 CN disclosed
WO-2019170590-A1 POLYURETHANE FOAMS BASED ON POLYETHERCARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2019-09-12 WO disclosed
EP-3068443-B1 RESIDUALIZING LINKERS AND USES THEREOF CENTRE FOR PROBE DEV AND COMMERCIALIZATION (CA) 2019-04-10 EP disclosed
CN-108699428-A Refrigerant mixtures comprising difluoromethane, pentafluoroethane, tetrafluoroethane, tetrafluoropropene and carbon dioxide and uses thereof 科慕埃弗西有限公司 2018-10-23 CN disclosed
EP-2760856-B1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2016-09-14 EP disclosed
US-8722670-B2 Selective NR2B antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-13 US disclosed
US-20130085138-A1 Selective NR2B Antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-04 US disclosed
US-20060035279-A1 Anti-GPE antibodies, their uses and assays for weakly immunogenic molecules NEUREN PHARMACEUTICALS LTD. (NZ) 2006-02-16 US disclosed
EP-1414804-A1 ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2004-05-06 EP disclosed
WO-2002034721-A1 ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-05-02 WO disclosed
US-6291504-B1 POTENT INHIBITORS OF THE CLASS OF ENZYMES KNOWN AS CYCLIN DEPENDENT KINASES DUPONT PHARMACEUTICALS COMPANY 2001-09-18 US disclosed
EP-0648612-B1 Reversible heat-sensitive recording material MITSUBISHI PAPER MILLS LTD (JP) 1998-06-10 EP disclosed
EP-0721146-A2 Hydrazide redox-dye-releasing compounds for photothermographic elements MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-07-10 EP disclosed
US-5498772-A SUBSTRATE WITH HEAT SENSITIVE LAYER AND OPTICAL RECORDING LAYER MITSUBISHI PAPER MILLS LIMITED (JP) 1996-03-12 US disclosed
US-5492803-A Hydrazide redox-dye-releasing compounds for photothermographic elements MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-02-20 US disclosed
EP-0648612-A1 Reversible heat-sensitive recording material MITSUBISHI PAPER MILLS, LTD. (JP) 1995-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085138-A1 Selective NR2B Antagonists GRIN2B, GRIN2A, GRIN3A HDAC2 865/4885HDAC8 1047/4885CYP3A4 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.